NASDAQ:ESTA Establishment Labs - ESTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Establishment Labs Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $70.95 +1.70 (+2.45%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$68.51▼$71.0050-Day Range$65.69▼$74.4752-Week Range$44.03▼$93.80Volume122,440 shsAverage Volume134,646 shsMarket Capitalization$1.73 billionP/E RatioN/ADividend YieldN/APrice Target$100.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Establishment Labs MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside42.2% Upside$100.86 Price TargetShort InterestBearish9.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 4 Articles This WeekInsider TradingSelling Shares$254,184 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.73) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector795th out of 1,005 stocksSurgical Appliances & Supplies Industry15th out of 21 stocks 3.4 Analyst's Opinion Consensus RatingEstablishment Labs has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $100.86, Establishment Labs has a forecasted upside of 42.2% from its current price of $70.95.Amount of Analyst CoverageEstablishment Labs has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.63% of the float of Establishment Labs has been sold short.Short Interest Ratio / Days to CoverEstablishment Labs has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in Establishment Labs has recently increased by 0.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEstablishment Labs does not currently pay a dividend.Dividend GrowthEstablishment Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ESTA. Previous Next 2.3 News and Social Media Coverage News SentimentEstablishment Labs has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Establishment Labs this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Establishment Labs to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Establishment Labs insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $254,184.00 in company stock.Percentage Held by Insiders12.39% of the stock of Establishment Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.26% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Establishment Labs are expected to grow in the coming year, from ($2.73) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Establishment Labs is -23.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Establishment Labs is -23.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Establishment Labs (NASDAQ:ESTA) StockEstablishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.Read More Receive ESTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Establishment Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address ESTA Stock News HeadlinesMarch 24, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for Establishment Labs Holdings (ESTA)March 23, 2023 | finance.yahoo.comWhat's Going On With Block Shares?March 25, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 22, 2023 | marketwatch.comMedical Cosmetic Surgery Implants Market: Forecast for 2023-2027 with Emerging TechnologiesMarch 11, 2023 | benzinga.comROSEN, A Top Ranked Law Firm, Encourages Establishment Labs Holdings Inc. Investors to Inquire About Securities Class Action Investigation - ESTAMarch 11, 2023 | finance.yahoo.comEstablishment Labs Holdings Inc. (NASDAQ:ESTA) Q4 2022 Earnings Call TranscriptMarch 6, 2023 | seekingalpha.comEstablishment Labs: More Constructive, But Not At 10x SalesMarch 2, 2023 | businesswire.comESTA INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Establishment Labs Holdings Inc. Investors to Inquire About Securities Class Action Investigation – ESTAMarch 25, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 1, 2023 | benzinga.comEstablishment Labs Submitted The Fourth And Final Module Of Its Modular Submission To The FDA For Premarket Approval Of Motiva Implants In The U.SMarch 1, 2023 | benzinga.comEstablishment Labs Sees FY23 Revenue $200M-$210M Vs $205.03M Est.March 1, 2023 | finance.yahoo.comEstablishment Labs Holdings Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 28, 2023 | finance.yahoo.comEstablishment Labs to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 28, 2023 | finance.yahoo.comEstablishment Labs to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 28, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Establishment Labs Holdings (ESTA)February 27, 2023 | msn.comEstablishment Labs GAAP EPS of -$0.55 beats by $0.13, revenue of $43.81M beats by $0.73MFebruary 27, 2023 | finance.yahoo.comDoes Establishment Labs Holdings Inc. (ESTA) Have the Potential to Rally 43.03% as Wall Street Analysts Expect?February 27, 2023 | finance.yahoo.comEstablishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Year 2022 Financial ResultsFebruary 23, 2023 | benzinga.comROSEN, National Trial Lawyers, Encourages Establishment Labs Holdings Inc. Investors to Inquire About Securities Class Action Investigation - ESTAFebruary 21, 2023 | marketwatch.comBrest Augmentation Implants Market Booming With Rising Demands and Massive Opportunities, 2023 - 2028February 20, 2023 | marketwatch.comBreastProsthesis Market Future Trends Demand 2023, and Forecast to 2028February 14, 2023 | finance.yahoo.comEstablishment Labs Holdings' (NASDAQ:ESTA) investors will be pleased with their stellar 176% return over the last three yearsFebruary 13, 2023 | wsj.comEstablishment Labs Holdings Inc.February 13, 2023 | finance.yahoo.comEstablishment Labs to Announce Fourth Quarter 2022 Financial Results on February 27February 9, 2023 | msn.comWall Street Analysts Predict a 42.71% Upside in Establishment Labs Holdings Inc. (ESTA): Here's What You Should KnowFebruary 9, 2023 | finance.yahoo.comWall Street Analysts Predict a 42.71% Upside in Establishment Labs Holdings Inc. (ESTA): Here's What You Should KnowJanuary 30, 2023 | marketwatch.comBrest Augmentation Implants Market Size Top manufacturers Entry, Market Share, Growth, Trends, Segmentation and Forecast 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ESTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Establishment Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address ESTA Company Calendar Last Earnings2/27/2023Today3/25/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESTA CUSIPN/A CIK1688757 Webwww.establishmentlabs.com Phone(062) 434-2400FaxN/AEmployees746Year FoundedN/APrice Target and Rating Average Stock Price Forecast$100.86 High Stock Price Forecast$125.00 Low Stock Price Forecast$65.00 Forecasted Upside/Downside+42.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,210,000.00 Net Margins-46.51% Pretax Margin-45.04% Return on Equity-422.08% Return on Assets-32.53% Debt Debt-to-Equity Ratio97.56 Current Ratio3.85 Quick Ratio2.91 Sales & Book Value Annual Sales$161.70 million Price / Sales10.71 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / Book-208.68Miscellaneous Outstanding Shares24,420,000Free Float21,393,000Market Cap$1.73 billion OptionableNot Optionable Beta1.03 Key ExecutivesJuan José Chacón QuirósChief Executive Officer & DirectorPaul D. RodioChief Operating OfficerRaj DenhoyChief Financial OfficerRoberto de MezervilleChief Technology OfficerS. Ross MansbachChief Compliance Officer & General CounselKey CompetitorsAvanos MedicalNYSE:AVNSEnovisNYSE:ENOVSpringWorks TherapeuticsNASDAQ:SWTXEmbectaNASDAQ:EMBCXencorNASDAQ:XNCRView All CompetitorsInsiders & InstitutionsLeslie GillinSold 3,759 sharesTotal: $254,183.58 ($67.62/share)Voya Investment Management LLCBought 9,531 shares on 2/28/2023Ownership: 1.118%Schonfeld Strategic Advisors LLCSold 1,500 shares on 2/15/2023Ownership: 0.292%Jane Street Group LLCSold 400 shares on 2/15/2023Ownership: 0.000%Legal & General Group PlcBought 157 shares on 2/15/2023Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions ESTA Stock - Frequently Asked Questions Should I buy or sell Establishment Labs stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ESTA shares. View ESTA analyst ratings or view top-rated stocks. What is Establishment Labs' stock price forecast for 2023? 5 Wall Street research analysts have issued 1 year target prices for Establishment Labs' stock. Their ESTA share price forecasts range from $65.00 to $125.00. On average, they predict the company's stock price to reach $100.86 in the next twelve months. This suggests a possible upside of 42.2% from the stock's current price. View analysts price targets for ESTA or view top-rated stocks among Wall Street analysts. How have ESTA shares performed in 2023? Establishment Labs' stock was trading at $65.65 at the beginning of the year. Since then, ESTA shares have increased by 8.1% and is now trading at $70.95. View the best growth stocks for 2023 here. When is Establishment Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our ESTA earnings forecast. How were Establishment Labs' earnings last quarter? Establishment Labs Holdings Inc. (NASDAQ:ESTA) issued its quarterly earnings data on Monday, February, 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.16. The business had revenue of $43.81 million for the quarter, compared to analysts' expectations of $43.70 million. Establishment Labs had a negative net margin of 46.51% and a negative trailing twelve-month return on equity of 422.08%. What ETFs hold Establishment Labs' stock? ETFs with the largest weight of Establishment Labs (NASDAQ:ESTA) stock in their portfolio include Simplify Health Care ETF (PINK), First Trust IPOX Europe Equity Opportunities ETF (FPXE), Nuveen Small Cap Select ETF (NSCS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Small Cap Equity Factor ETF (SMLF).Vanguard Health Care ETF (VHT) and What guidance has Establishment Labs issued on next quarter's earnings? Establishment Labs updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million. What other stocks do shareholders of Establishment Labs own? Based on aggregate information from My MarketBeat watchlists, some companies that other Establishment Labs investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Sientra (SIEN), Allergan (AGN), BCE (BCE), Canadian Imperial Bank of Commerce (CM), Conduent (CNDT), Canadian Natural Resources (CNQ), Chevron (CVX) and Evolus (EOLS). When did Establishment Labs IPO? (ESTA) raised $50 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and BTIG was co-manager. What is Establishment Labs' stock symbol? Establishment Labs trades on the NASDAQ under the ticker symbol "ESTA." Who are Establishment Labs' major shareholders? Establishment Labs' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (6.08%), Cowen AND Company LLC (3.52%), Neuberger Berman Group LLC (2.71%), UBS Group AG (1.65%), Morgan Stanley (1.24%) and Artisan Partners Limited Partnership (1.17%). Insiders that own company stock include Dennis E Condon, Dennis E Condon, Edward J Schutter, Jw Asset Management, Llc, Leslie Gillin, Lisa Gersh, Mezerville Roberto De, Nicholas Sheridan Lewin, Quiros Juan Jose Chacon, Renee Gaeta and Santos Salvador Dada. View institutional ownership trends. How do I buy shares of Establishment Labs? Shares of ESTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Establishment Labs' stock price today? One share of ESTA stock can currently be purchased for approximately $70.95. How much money does Establishment Labs make? Establishment Labs (NASDAQ:ESTA) has a market capitalization of $1.73 billion and generates $161.70 million in revenue each year. The company earns $-75,210,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis. How many employees does Establishment Labs have? The company employs 746 workers across the globe. How can I contact Establishment Labs? Establishment Labs' mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The official website for the company is www.establishmentlabs.com. The company can be reached via phone at (062) 434-2400 or via email at ir@establishmentlabs.com. This page (NASDAQ:ESTA) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.